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SECTION	1:	ADMINISTRATIVE	INFORMATION	
	
Title:		Chronic	Headache	and	Self-management	Study	(CHESS)	
	
ISRCTN	number:	79708100	
	
SAP	Version:	Version	1.1	(Date:	16	July	2019)	
	
Protocol	Version:	Version	3.4	(Date:	12	July	2018)	
	
SAP	revisions:	None	
	
Roles	and	responsibility:		
• Dr	Dipesh	Mistry,	Warwick	Clinical	Trials	Unit	(WCTU)	–	Trial	Statistician	(Author	of	
SAP)	
• Dr	Siew	Wan	Hee,	Warwick	Medical	School	(WMS)	–	Statistician	(Co-applicant)	
• Professor	Sandra	Eldridge,	Barts	and	The	London	School	of	Medicine	and	Dentistry	–	
Senior	Statistician	(Co-applicant)	
• Professor	Martin	Underwood,	Warwick	Clinical	Trials	Unit	(WCTU)	–	Principal	
Investigator	
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SECTION	2:	INTRODUCTION	
	
	
Background	and	rationale	
Chronic	headaches	present	a	major	problem	both	for	the	individual	and	society.	Previous	
studies	on	supportive	self-management	interventions	in	this	population	have	largely	been	
small	studies	with	short	term	follow-up,	they	often	did	not	report	clinically	relevant	
outcomes,	or	were	conducted	in	different	healthcare	systems	therefore	difficult	to	translate	
into	an	NHS	setting.	These	studies	also	did	not	necessarily	focus	on	chronic	headache	but	
rather	looked	at	headache	with	no	frequency	specified.	Based	on	the	results	of	our	
systematic	review	there	may	be	potential	for	large	gain	through	a	combination	of	self-
management	education	and	appropriate	use	of	prophylaxis	and	management	of	medication	
overuse	headache	in	a	chronic	headache	population.	
	
In	order	to	develop	the	evidence	base	needed	for	self-management	intervention	for	chronic	
headache	there	needs	to	be	a	carefully	developed,	piloted	and	evaluated	intervention	
package	which	has	been	supported	by	good	qualitative	work	on	understanding	outcomes	of	
interest.	There	is	therefore	the	need	for	a	robust	clinical	and	cost-effectiveness	trial	within	
an	NHS	setting.	
	
Objectives	
The	objective	is	to	answer	the	question:	Amongst	adults	with	chronic	headache	arising	from	
migraine,	chronic	tension	type	headache	or	medication	overuse	headache,	is	the	provision	
of	a	self-management	support	programme	in	addition	to	best	usual	NHS	care	clinically	and	
cost	effective?	
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SECTION	3:	STUDY	METHODS	
	
Trial	design	
This	trial	is	a	multi-centre	randomised	controlled	trial	comparing	a	group	education	and	self-
management	intervention	with	a	best	usual	care	plus	relaxation	control	for	participants	
living	with	chronic	tension	type	headaches,	probable	chronic	migraine	or	definite	chronic	
migraine	with	or	without	medication	overuse	headache.	
	
Randomisation	
The	randomisation	allocation	ratio	is	1:1.07	due	to	the	method	used	to	compute	the	sample	
size	with	clustering	in	one	arm.	Randomisation	will	be	stratified	by	geographical	locality	
(Midlands	and	Greater	London)	and	headache	type	(six	possible	headache	types;	chronic	
tension	type	headache,	probable	chronic	migraine	and	definite	chronic	migraine	with	or	
without	medication	overuse	headache)	using	minimisation.	Randomisation	will	take	place	
using	an	online	application	specifically	developed	for	the	CHESS	Study	by	the	Warwick	CTU	
programming	team.	(See	section	2.6.3	of	the	protocol).	
	
Sample	size	
A	detailed	description	of	the	sample	size	calculation	can	be	found	in	section	5.8	of	the	
protocol.	In	brief,	a	sample	size	of	689	(333	in	the	relaxation	arm	and	356	in	the	self-
management	programme)	will	provide	90%	power	to	detect	a	between	group	difference	in	
those	with	migraine	of	2	(SD:	6.9)	in	the	HIT-6	score	measured	at	12	months	at	the	two-
sided	5%	significance	level.	The	sample	size	also	accounted	for	20%	loss	to	follow-up	and	
clustering	in	the	self-management	arm	using	an	intra-class	correlation	coefficient	(ICC)	of	
0.01	assuming	an	average	group	size	of	10.	
	
Framework	
A	superiority	hypothesis	testing	framework	will	be	used	to	compare	the	self-management	
arm	to	the	relaxation	arm.		
	
Statistical	interim	analyses	and	stopping	guidance	
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There	are	no	planned	interim	analyses	or	stopping	guidelines	for	this	study.	However,	in	
consultation	with	the	Data	Monitoring	Committee	(DMC)	we	would	review	the	sample	size	
around	halfway	through	recruitment	to	ensure	we	have	sufficient	participants	with	probable	
or	definite	chronic	migraine.	If	the	proportion	of	participants	with	chronic	tension	type	
headache	is	≤	15%	then	we	will	recruit	more	participants	with	probable	or	definite	chronic	
migraine	such	that	we	could	perform	the	primary	clinical	analysis	on	this	subpopulation.	
	
Timing	of	final	analysis	
Once	all	of	the	data	has	been	collected	from	participants,	entered	onto	the	database,	fully	
validated	and	cleaned,	the	database	will	then	be	locked.	The	final	analyses	on	all	outcomes	
will	then	be	conducted	at	each	of	the	follow-up	time	points.		
	
Timing	of	outcome	assessments	
Primary	and	secondary	outcomes	will	be	collected	at	baseline,	4,	8	and	12	months	follow-
up.		
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SECTION	4:	STATISTICAL	PRINCIPLES	
	
	
Confidence	intervals	and	P	values	
All	statistical	tests	will	be	two-sided	at	the	5%	significance	level.	The	estimate,	95%	
confidence	interval	(95%	CI)	and	P	value	will	be	reported	for	each	test	undertaken.		
	
Adherence	and	protocol	deviations	
We	will	look	at	two	levels	of	adherence	in	this	study;	minimal	adherence	and	full	adherence.	
Minimal	adherence	with	the	intervention	is	defined	as	the	participant	attending	day	1	of	the	
intervention	plus	the	one-to-one	session.	Full	adherence	is	defined	as	the	participant	
attending	both	days,	plus	individualised	contact	with	the	nurse.	Both	levels	of	adherence	
will	inform	the	complier	averaged	causal	effect	(CACE)	analysis.		
	
Analysis	populations	
All	 analyses	 will	 be	 available	 case	 analyses	 based	 on	 ‘Intention-to-treat’	 (ITT)	 principles.	
Participants	 will	 be	 analysed	 according	 to	 the	 treatment	 they	 were	 randomised	 to,	
irrespective	of	the	treatment	they	actually	received.	All	participants	will	be	included	in	the	
analysis,	regardless	of	whether	they	adhered	to	the	protocol.	The	main	summary	tables	and	
analyses	will	be	based	on	the	intention-to-treat	population.	
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SECTION	5:	TRIAL	POPULATION	
	
	
Screening	data	
A	detailed	summary	of	the	screening	data	will	be	presented	as	frequencies	and	percentages	
to	describe	the	representativeness	of	the	trial	sample.	The	screening	summary	will	start	at	
the	GP	practice	population	search	level	(i.e.	how	many	practices	were	approached,	the	
number	records	searched,	the	number	of	mail	outs	etc.)	right	the	way	through	to	final	
consent	and	randomisation.	This	will	also	include	a	summary	of	how	many	participants	were	
self-referrals	and	how	many	were	approached	via	the	GP	practice.	
	
Eligibility	
Patients	are	eligible	to	be	included	in	the	trial	if	they	meet	the	following	criteria:		
Inclusion	criteria		
• Able	and	willing	to	comply	with	the	study	procedures	and	provision	of	written	
informed	consent.		
• Aged	≥18	years.		
• Living	with	chronic	headache;	defined	as	headache	on	15	or	more	days	per	month	
for	at	least	three	months.		
• Result	of	nurse	classification	interview	confirms	headache	type	to	be	definite	or	
probable	chronic	migraine,	or	chronic	tension	type	headache,	with	or	without	
medication	overuse	headache.		
• Fluent	in	written	and	spoken	English.		
	
Exclusion	criteria		
• Unable	to	attend	the	group	sessions.		
• No	access	to	a	telephone.		
• Has	an	underlying	serious	psychological	disorder	with	ongoing	symptoms	which	
preclude	or	significantly	interfere	with	participation	in	the	group	intervention.		
• Previous	entry	or	randomisation	in	the	present	trial.		
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• Is	currently	participating	in	another	clinical	trial	of	headache	treatments,	or	in	a	trial	
of	an	unregistered	medicinal	product,	or	less	than	90	days	have	passed	since	
completing	participation	in	such	a	trial.		
	
The	eligibility	will	be	summarised	using	frequencies	and	percentages	to	describe	how	many	
people	were:	
- Eligible	and	randomised	
- Eligible	and	not	randomised		
- Ineligible	and	randomised	(in	error)	
- Ineligible	and	not	randomised;	summarising	the	main	reasons	for	exclusion		
	
In	addition	to	the	above,	a	summary	of	the	different	headache	types	identified	from	the	
nurse	classification	interviews	will	also	be	presented	(definite	or	probable	chronic	migraine,	
or	chronic	tension	type	headache,	with	or	without	medication	overuse).		
	
Recruitment	
The	CONSORT	diagram	will	illustrate	the	flow	of	participants	throughout	the	trial.	This	will	
include:	
- Number	screened	
- Of	those	screened,	how	many	ineligible	or	declined		
- Number	randomised	
- How	many	withdrew,	died	and	were	lost	to	follow-up	at	each	follow-up	time-point	
- How	many	included	in	the	final	analyses	at	the	primary	endpoint	listing	reasons	why	
participants	were	excluded	
	
Withdrawal/follow-up	
All	withdrawals	will	be	summarised	by	group	using	frequencies	and	percentages.		
Level	of	withdrawal	-	will	be	summarised	by	treatment	group	i.e.	how	many	withdrew	from	
intervention	alone	but	remained	on	follow-up	and/or	how	many	withdrew	completely.	
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Timing	of	withdrawal	–	withdrawal	timings	in	this	trial	will	be	summarised	by	treatment	group	
as	follows:	
• Withdrawals	 after	 randomisation	 but	 before	 first	 group	 session	 (intervention	 arm	
only);	
• Withdrawals	during	group	sessions	(intervention	arm	only);	
• Withdrawals	from	follow-up	-	(i)	withdrawal	prior	to	4-month	follow-up	(ii)	withdrawal	
after	4-month	follow-up	but	before	8-month	follow-up	(iii)	withdrawal	after	8-month	
follow-up	but	before	12-month	follow-up	
Withdrawal	decision	–	 the	withdrawal	decision	 i.e.	decision	made	by	participant	or	CHESS	
study	team,	will	be	summarised	by	treatment	group	
Withdrawal	reason	–	participants	have	the	option	to	provide	a	reason	for	withdrawal	if	they	
withdraw.	Withdrawal	reasons	will	be	summarised.	
Follow-up	rates	-	follow-up	rates	are	based	on	case	report	form	(CRF)	completion	at	follow-
up	time	points.	
%	Follow-up	rate	(at	time	T)	=	 !"#$%&	()	*+&,-.-*+/,0	+00%00%1	+,	,-#%	22(,+3	/(.,5+,	05("31	5+6%	$%%/	+00%00%1	+,	,-#%	2 	×100	
Follow-up	rates	will	be	computed	at	the	4-,	8-	and	12-month	follow-up	time-points.	
	
Baseline	patient	characteristics	
The	 demographic	 characteristics	 and	 pre-randomisation	 clinical	 outcome	 measures	 of	 all	
randomised	participants	will	be	summarised	by	treatment	allocation.	The	table	below	lists	
the	demographic	and	clinical	measures	that	will	be	collected.	
Type	of	Data	 Outcome	measures	
Demographic:	 - Age	
- Gender	
- Ethnic	group	
- Age	at	leaving	full	time	education	
- Current	work	status	
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Clinical	measures:	 	
General	Health		 - Fatigue	
- Sleep	quality	
- Bodily	pain	
- Troublesomeness	grid	
Headache	Specific		 - Headache	Specific	Information	(HIT-6)[1]	
- Chronic	Headache	Quality	of	Life	
Questionnaire,	version1.0	(CHQLQ)	[2]	
- Headache	frequency,	severity	and	
duration	over	the	past	7	days	
Health-related	Quality	of	Life	 - Short	Form	12-item	Health	Survey	(SF12	
(v2))	[3]	
- EuroQoL	(EQ5D-5L)	[4]	
- Chronic	Headache	Quality	of	Life	
Questionnaire,	version1.0	(CHQLQ)	[2]	
Mood		 Hospital	Anxiety	and	Depression	Scale	(HADS)	
[5]	
	
Confidence		 Pain	Self-Efficacy	Questionnaire	(PSEQ)	[6]	
Social	Activity		 Social	Integration	Subscale	(heiQ)	[7]	
Health	economic	measures:	 	
Medication		 - Medication	purchased	in	last	four	weeks	
over	the	counter	
- Cost	
Healthcare	Use		 - Inpatient	care	
- Admission	details	
- NHS	Day	Care	treatment	
- Community	health	and	social	care	
- Side	effects	from	headache	medication	
- Private	treatment	
- Additional	cost	information	
	
For	continuous	data,	the	number	of	participants	(n),	mean,	standard	deviation	(SD),	median	
and	interquartile	range	(IQR)	will	be	used	to	summarise	the	outcome	measures	by	
treatment	allocation.	The	number	(%)	of	participants	will	be	used	to	summarise	categorical	
outcome	measures.			
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SECTION	6:	ANALYSIS	
	
	
Outcome	definitions	
The	table	below	lists	and	describes	the	primary	and	secondary	outcomes.	This	includes	
details	of	specification	of	outcomes,	timings	and	the	derivation	of	the	outcome	(if	required).	
	
Outcome	 Time	point	 Derivation	of	outcome	
Primary	outcome	 	 	
HIT-6	score[1]	 1,	2,	3,	4	 HIT-6	consists	of	6	questions,	each	with	5	responses	(never	
to	always)	which	are	scored	6,	8,	10,	11,	and	13	points	
respectively.	The	HIT-6	is	computed	by	simply	summing	the	
scores	across	the	6	questions.	The	score	ranges	from	36-78;	
the	higher	the	score	the	greater	the	severity	of	headache.	
Secondary	
outcomes	
	 	
Chronic	Headache	
Quality	of	Life	
Questionnaire,	
version1.0	(CHQLQ)	
1,	2,	3,	4	 Measures	chronic	headache	quality	of	life	on	scale	of	0-100	
over	3	domains	(role	restrictive,	role	preventive	and	
emotional	function).	A	higher	score	indicates	better	quality	
of	life.	
SF-12	V2	[3]	 1,	2,	3,	4	 SF-12	score	computed	using	the	algorithm/software	
provided	by	the	authors.	The	algorithm	produces	mental	and	
physical	component	scores	ranging	from	0-100	where	a	
higher	score	reflects	better	mental	and	physical	functioning,	
respectively.		
EQ-5D-5L	[4]	 1,	2,	3,	4	 EQ-5D-5L	score	will	be	computed	in	Stata	using	the	eq5d	
package.	The	EQ-5D-5L	score	ranges	from	0-1	where	a	
higher	score	reflects	better	quality	of	life.	
Hospital	Anxiety	
and	Depression	
Scale	(HADS)	[5]	
1,	2,	3,	4	 The	HADS	consists	of	14	questions	each	with	4	responses	
with	an	assigned	score.	Seven	questions	measure	anxiety	
and	the	other	seven	measure	depression.	The	scores	are	
simply	summed	up	to	give	an	anxiety	and	depression	score	
both	ranging	from	0-21	where	a	higher	score	reflects	more	
severe	anxiety	and	depression.	
Pain	Self-Efficacy	
Questionnaire	
(PSEQ)	[6]	
1,	2,	3,	4	 PSEQ	consists	of	10	questions,	each	with	6	responses	(Not	at	
all	confident	to	Completely	confident)	which	are	scored	from	
0-6	respectively.	The	PSEQ	is	computed	by	simply	summing	
the	scores	across	the	10	questions.	The	score	ranges	from	0-
60	where	higher	scores	reflect	stronger	self-efficacy	beliefs.	
Social	Integration	
Subscale	of	the	
Health	Education	
Impact	
Questionnaire	
(heiQ)	[7]	
1,	2,	3,	4	 The	Social	Integration	subscale	of	heiQ	measures	the	impact	
of	social	engagement	and	support	through	interaction	with	
others	presented	with	the	same	illness.	If	>50%	questions	
present	then	values	can	be	assigned	for	scoring	otherwise	
the	score	is	missing.	Higher	scores	indicate	higher	level	of	
social	interaction.	
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Headache	days	
(Collected	via	
smartphone	app	or	
paper	version)	
Once	a	week	for	
the	first	6	months	
and	then	once	a	
month	for	the	
following	6	
months.	Also	
collected	at	1,	2,	3,	
4.		
Data	collected	on:	
- On	how	many	of	the	last	7	days	have	you	had	a	
headache	
- On	those	days,	on	average	how	long	did	they	last	
- On	those	days,	on	average	how	severe	were	they	
Safety	reporting	 	 	
Adverse	Events	
and	Serious	
Adverse	Events	
Throughout	the	
trial	
	
1	Baseline		
2	4	month	after	randomisation		
3	8	months	after	randomisation	
4	12	months	after	randomisation		
	
Analysis	methods	
Participant	characteristics	and	outcomes	will	be	summarised	as	mean	and	standard	
deviation	(SD)	for	continuous	data	or	frequency	and	percentage	for	categorical	data,	
summarised	by	treatment	arm.	The	median	and	interquartile	range	(IQR)	will	be	presented	
if	data	are	non-normal.	
	
The	primary	analysis	approach	will	be	intention	to	treat.	To	account	for	the	trial	design	with	
clustering	in	the	intervention	arm,	linear	mixed	effects	models	with	partial	clustering	will	be	
used	to	estimate	treatment	effects	for	both	primary	and	secondary	outcomes.	This	will	be	
done	using	the	mixed	command	in	Stata.	Analyses	will	be	adjusted	for	age,	gender,	the	
baseline	value	of	the	dependent	variable	and	baseline	stratification	factors	(type	of	
headache	and	geographical	locality).	The	adjusted	treatment	effect	estimates	(mean	
difference)	will	be	presented	along	with	their	associated	95%	confidence	interval	(CI).	The	
primary	clinical	analysis	will	assess	the	overall	difference	between	the	self-management	
therapy	(intervention)	and	the	relaxation	therapy	(control)	groups	in	the	population	with	
either	probable	or	definite	chronic	migraine	(if	the	proportion	of	participants	with	chronic	
tension	type	headache	is	≤15%).	If	the	proportion	of	chronic	tension	type	headache	is	>15%	
then	the	primary	analysis	will	be	according	to	the	whole	population	of	chronic	headache	
(chronic	migraine	and	tension	type	headache).	
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The	values	of	the	variable	“number	of	headache	days	in	the	past	month”	collected	at	
baseline	and	each	follow-up	time	point	is	in	the	range	0	to	28.	As	such	a	normal	distribution	
may	not	be	a	suitable	distribution	to	explain	its	frequency.	We	will	therefore	plot	the	
frequency	of	headache	days	and	explore	whether	other	distributions,	e.g.	negative	binomial	
and	beta-binomial	may	be	able	to	explain	the	data	frequency.	The	plots	will	be	examined	
visually	before	a	distribution	is	assumed	for	the	variable	for	further	analysis.	If	more	than	
one	distribution	is	considered	to	be	sufficient	for	the	data	then	they	will	be	used	for	further	
analyses	and	all	the	results	will	be	presented.	We	may	also	explore	the	possibility	of	
transforming	the	number	of	headache	day’s	data	into	proportion	(or	rates)	or	categorising	
the	data	into	ordinal	outcomes.	The	latter	approach	would	decrease	the	precision	and	
sensitivity	of	the	outcome	but	may	be	better	than	assuming	it	follows	an	incorrect	
distribution.	
	
The	possibility	of	carrying	out	a	complier	averaged	causal	effect	(CACE)	analysis	for	the	
primary	outcome	will	be	explored.	Pre-specified	subgroup	analyses	will	also	be	conducted	
using	formal	statistical	tests	for	interaction	to	examine	whether	baseline	anxiety,	depression	
and	severity	are	moderators	of	treatment	effect.[8]		
	
Missing	data	
The	levels	and	patterns	of	non-responders	at	each	follow-up	time	point	(including	the	
weekly/monthly	headache	days	collected	via	the	smartphone	app)	will	be	monitored	
regularly.	This	is	to	ensure	that	strategies	could	be	identified	and	implemented	to	minimise	
non-responders.	
	
The	levels	and	patterns	of	missingness	in	the	primary	outcome	will	be	assessed	to	
determine	the	type	of	missingness	(e.g.	MAR,	NMAR).		If	required,	as	an	additional	
sensitivity	analysis,	imputation	techniques	relevant	to	the	type	of	missing	data	mechanism	
will	be	used	to	impute	data	and	estimate	the	treatment	effect	to	see	how	it	compares	to	the	
main	ITT	analysis.		
	
Additional	analyses	
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In	addition	to	the	primary	analyses,	the	overall	result	for	those	with	all	headache	types	will	
also	be	assessed.	NICE	was	specifically	interested	in	data	on	specific	headache	types;	
rejecting	data	that	reported	data	on	a	mixed	population	of	people	with	chronic	headaches.	
Therefore	in	addition	to	the	primary	analyses,	the	results	(mean	difference	and	95%	CI)	for	
each	of	the	three	headache	types	separately,	and	the	results	for	those	with	or	without	
medication	overuse	separately	will	also	be	presented	to	facilitate	future	meta-analyses	and	
inform	future	condition	specific	guidelines.	
	
Data	on	total	headache	days	was	collected	from	participants	over	the	whole	study	period.	
Participants	had	a	choice	of	reporting	this	outcome	either	using	a	smartphone	app	or	diary	
records	(not	both).		This	data	was	also	collected	in	the	baseline	and	follow-up	
questionnaires.	We	will	compare	the	total	headache	days	between	the	two	groups	using	an	
area	under	the	curve	(AUC)	approach.	If	participants	have	reported	headache	days	data	
using	both	the	app/diary	and	the	follow-up	form	at	the	same	time	point,	then	we	will	use	
the	app/diary	as	the	primary	data	source.	We	expect	there	will	be	missing	data.	Therefore	
we	will	apply	the	following	scoring	algorithm	in	order	to	obtain	a	complete	set	or	scores	for	
each	participant	thus	allowing	us	to	undertake	the	AUC	analysis.	
	
• A	blank	score	for	each	expected	observation	is	created.		
• If	there	is	a	valid	text	message	response	for	the	expected	observation,	then	the	blank	
value	is	replaced	with	the	text	message	score.		
• If	the	participant	did	not	register	with	the	text	messaging	service	and	there	is	a	valid	
paper	diary	score,	then	the	blank	value	is	replaced	with	this	paper	diary	score.	
• If	the	participant	did	not	provide	a	score	via	either	the	text	messaging	service	or	the	
diary,	but	a	valid	score	is	available	on	the	follow-up	form,	then	the	blank	value	is	
replaced	with	the	follow-up	form	score.	
• If	the	participant	has	completed	only	one	data	source	(either	text	message	or	paper	
diaries)	and	observation	X	is	missing	in	the	middle	of	the	data	set,	then	the	score	for	
observation	X	is	calculated	as:		(;<=	>	?@)	B	(;<=	>	B@)C 			 	 (1)	
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• If	two	or	more	adjacent	scores	are	missing,	then	a	monotonic	assumption	is	made	
for	the	missing	values	between	the	most	recent	valid	score	and	the	next	available	
valid	score.	For	example	if	two	consecutive	scores	are	missing,	observation	X	and	
observation	X	+	1,	then	the	scores	for	observation	X	–	1	and	observation	X	+	2	are	
used	to	calculate	the	imputed	values	for	observations	X	and	day	X	+	1	as	follows:		
	 𝑂𝑏𝑠	𝑋 = 𝑂𝑏𝑠	𝑋 − 1 +	 𝑂𝑏𝑠	𝑋 + 	2 −	 𝑂𝑏𝑠	𝑋 − 1𝑁𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑚𝑖𝑠𝑠𝑖𝑛𝑔	𝑜𝑏𝑠 + 1									(2)	
	 𝑂𝑏𝑠	𝑋 + 1 = 𝑂𝑏𝑠	𝑋 +	 𝑂𝑏𝑠	𝑋 + 	2 −	 𝑂𝑏𝑠	𝑋 − 1𝑁𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑚𝑖𝑠𝑠𝑖𝑛𝑔	𝑜𝑏𝑠 + 1									(3)	
	
• If	the	participant	has	provided	a	score	via	both	app/diary	and	the	follow-up	data,	
then	the	app/diary	data	is	used.	
• If	the	participant	has	complete	both	data	sources	but	the	app/diary	score	is	missing,	
then	the	follow-up	data	score	is	used.		
• If	the	first	observation	is	missing	then	the	first	valid	observation	for	this	participant	is	
backfilled.		
• If	last	expected	observation	is	missing,	then	the	score	from	the	12	month	follow-up	
will	be	used.	If	this	score	is	missing	then	the	last	observation	carried	forward	is	used.	
	
Around	30	participants	will	be	included	in	the	process	evaluation	interviews	conducted	from	
pre-randomisation	to	follow-up.	It	is	possible	that	discussing	their	expectations	before	and	
during	the	study	may	influence	the	treatment	effectiveness.	A	sensitivity	analysis	will	
therefore	be	performed	that	excludes	these	participants	from	the	main	analysis.		
	
At	the	eligibility	check,	participants	are	eligible	if	they	have	chronic	headache	defined	as	15	
or	more	days	of	headache	per	month	for	at	least	three	months.	However	on	the	baseline	
form,	participants	are	asked	to	report	the	number	of	headache	days	over	the	last	4	weeks	
for	which	many	report	having	less	than	15	days	of	headache.	A	sensitivity	analysis	will	
therefore	be	performed	that	excludes	these	participants	from	the	main	analysis.		
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Harms	
The	frequency	and	percentage	(%)	of	serious	adverse	events	(SAE)	and	adverse	events	(AE)	
in	the	trial	will	be	compared	between	the	two	treatments	using	the	chi-squared	test	
provided	the	expected	values	in	the	cross-tabulation	are	greater	than	five,	otherwise	
Fisher’s	exact	test	will	be	used.	Odds	ratios	and	95%	confidence	intervals	will	be	reported.	
Adjusted	analyses	will	not	be	performed	for	any	harm	data.	The	event	type,	severity	
assessment,	expectedness	and	relatedness	to	intervention	will	also	be	summarised	by	
treatment	arm.		
	
Statistical	software	
Statistical	analyses	will	be	conducted	using	the	statistical	software	package	Stata	15.0.	
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SECTION	7:	TEMPLATE	TABLES	AND	FIGURES	
	
The	template	tables	and	figures	have	been	presented	in	a	separate	document	that	consists	
of	the	following	sections:	
	
SECTION	1	-	Screening	through	to	randomisation	
SECTION	2	-	Participant	baseline	and	demographic	data	
SECTION	3	-	Participant	follow-up	
SECTION	4	-	Intervention	data	
SECTION	5	-	Study	outcome	data	 	
SECTION	6	-	Adverse	events	and	serious	adverse	events	
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